Objectives: Monkeypox is now regarded as a major global public health concern. A common symptom of this disease is an acute febrile illness with skin sores. The likelihood of the virus spreading from person to person is increasing. The aim of the present study is to estimate the protective immunity rate against monkeypox.
Methods: Based on the current situation in Africa, the authors forecast the protective immunity rate against monkeypox for the present and future if a smallpox vaccination booster is not available. The clinical mathematical model was used. The primary data for analysis include data on the current serological rate against smallpox and data on the declining rate of smallpox immunity after the last vaccination.
Results: According to the current clinical modeling study, protective immunity to monkeypox is limited. The rate among people who have previously been immunized against smallpox is still higher than the general population rate. If the present monkeypox outbreak (2022) is not successfully controlled, there could be a severe public health danger, such as a pandemic. On a larger scale, in a few years, no immunity will be a concern.
Conclusions: To suppress the current monkeypox outbreak, it may be necessary to research the use of a novel monkeypox immunization or a traditional smallpox vaccine.
{"title":"Protective immunity rate against monkeypox: expectation for present and future in case that there is no smallpox vaccine booster.","authors":"Pathum Sookaromdee, Viroj Wiwanitkit","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong>Monkeypox is now regarded as a major global public health concern. A common symptom of this disease is an acute febrile illness with skin sores. The likelihood of the virus spreading from person to person is increasing. The aim of the present study is to estimate the protective immunity rate against monkeypox.</p><p><strong>Methods: </strong>Based on the current situation in Africa, the authors forecast the protective immunity rate against monkeypox for the present and future if a smallpox vaccination booster is not available. The clinical mathematical model was used. The primary data for analysis include data on the current serological rate against smallpox and data on the declining rate of smallpox immunity after the last vaccination.</p><p><strong>Results: </strong>According to the current clinical modeling study, protective immunity to monkeypox is limited. The rate among people who have previously been immunized against smallpox is still higher than the general population rate. If the present monkeypox outbreak (2022) is not successfully controlled, there could be a severe public health danger, such as a pandemic. On a larger scale, in a few years, no immunity will be a concern.</p><p><strong>Conclusions: </strong>To suppress the current monkeypox outbreak, it may be necessary to research the use of a novel monkeypox immunization or a traditional smallpox vaccine.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"12 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017919/pdf/ajcei0012-0001.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9146239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: PD1/PDL1 pathway targeting using antibodies shows immune related adverse events in patients with tumors. The masking of PD1 ligand by soluble human PD-1 (shPD-1) probably inhibits the PD1/PDL1 interaction between T cells and tumor cells. Accordingly, the goal of this study was to produce human recombinant PD-1-secreting cells and find out how soluble human PD-1 affects T lymphocyte function.
Methods: An inducible construct of the human PD-1 secreting gene under hypoxia condition was synthesized. The construct was transfected into the MDA-MB-231 cell line. In six groups exhausted T lymphocytes were co-cultured with transfected or non-transfected MDA-MB-231 cell lines. The effect of shPD-1 on IFNγ production, Treg cell's function, CD107a expression, apoptosis, and proliferation was assessed by ELISA and flow cytometry, respectively.
Results: The results of this study showed that shPD-1 inhibits PD-1/PD-L1 interaction and enhances T lymphocyte responses through a significant increase in IFNγ production and CD107a expression. In addition, in the presence of shPD-1, the percentage of Treg cells decreased, while MDA-MB-231 cell apoptosis increased.
Conclusions: We concluded that the human PD-1 secreting construct induced under hypoxia condition inhibits the interaction of PD-1/PD-L1 and enhances T lymphocyte responses in tumor environments and chronic infections.
{"title":"Human recombinant soluble PD1 can interference in T cells and Treg cells function in response to MDA-MB-231 cancer cell line.","authors":"Samaneh Mohammadzadeh, Alireza Andalib, Hossein Khanahmad, Nafiseh Esmaeil","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong>PD1/PDL1 pathway targeting using antibodies shows immune related adverse events in patients with tumors. The masking of PD1 ligand by soluble human PD-1 (shPD-1) probably inhibits the PD1/PDL1 interaction between T cells and tumor cells. Accordingly, the goal of this study was to produce human recombinant PD-1-secreting cells and find out how soluble human PD-1 affects T lymphocyte function.</p><p><strong>Methods: </strong>An inducible construct of the human PD-1 secreting gene under hypoxia condition was synthesized. The construct was transfected into the MDA-MB-231 cell line. In six groups exhausted T lymphocytes were co-cultured with transfected or non-transfected MDA-MB-231 cell lines. The effect of shPD-1 on IFNγ production, Treg cell's function, CD107a expression, apoptosis, and proliferation was assessed by ELISA and flow cytometry, respectively.</p><p><strong>Results: </strong>The results of this study showed that shPD-1 inhibits PD-1/PD-L1 interaction and enhances T lymphocyte responses through a significant increase in IFNγ production and CD107a expression. In addition, in the presence of shPD-1, the percentage of Treg cells decreased, while MDA-MB-231 cell apoptosis increased.</p><p><strong>Conclusions: </strong>We concluded that the human PD-1 secreting construct induced under hypoxia condition inhibits the interaction of PD-1/PD-L1 and enhances T lymphocyte responses in tumor environments and chronic infections.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"12 2","pages":"11-23"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195389/pdf/ajcei0012-0011.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9504368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Monkey pox has expanded across Europe as a result of the widespread outbreak, creating a severe public health risk. Monkey pox is an uncommon pox infection that has reappeared due to zoonosis. Monkey pox has spread over Europe and North America, posing a serious public health risk. The regular smallpox vaccine has been shown to be effective against monkeypox. The suspension of smallpox immunization is currently being debated due to the possibility of a connection with the current monkeypox outbreak. In clinical immunology, the link between a desire for smallpox vaccination, low population immunity, and a higher incidence of monkeypox is an intriguing topic.
Methods: This is a descriptive analysis done in the past. The writers investigate the situation in West Africa in this research. The available data on monkeypox incidence in an African endemic area was reassessed.
Results: Based on a recent analysis of epidemiological data from an endemic area, there is no indication of a yearly ongoing increase in monkeypox incidence following the discontinuation of the smallpox vaccine, and incidence varies.
Conclusion: There is no evidence of an annual increase in monkeypox incidence following the withdrawal of smallpox immunization.
{"title":"Smallpox vaccination discontinuation and monkeypox incidence in an African endemic region: a reanalysis on the relationship between the withdrawal of smallpox vaccine and subsequent morbidity.","authors":"Rujittika Mungmunpuntipantip, Viroj Wiwanitkit","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Monkey pox has expanded across Europe as a result of the widespread outbreak, creating a severe public health risk. Monkey pox is an uncommon pox infection that has reappeared due to zoonosis. Monkey pox has spread over Europe and North America, posing a serious public health risk. The regular smallpox vaccine has been shown to be effective against monkeypox. The suspension of smallpox immunization is currently being debated due to the possibility of a connection with the current monkeypox outbreak. In clinical immunology, the link between a desire for smallpox vaccination, low population immunity, and a higher incidence of monkeypox is an intriguing topic.</p><p><strong>Methods: </strong>This is a descriptive analysis done in the past. The writers investigate the situation in West Africa in this research. The available data on monkeypox incidence in an African endemic area was reassessed.</p><p><strong>Results: </strong>Based on a recent analysis of epidemiological data from an endemic area, there is no indication of a yearly ongoing increase in monkeypox incidence following the discontinuation of the smallpox vaccine, and incidence varies.</p><p><strong>Conclusion: </strong>There is no evidence of an annual increase in monkeypox incidence following the withdrawal of smallpox immunization.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"11 5","pages":"78-83"},"PeriodicalIF":0.0,"publicationDate":"2022-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678744/pdf/ajcei0011-0078.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40481932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background/objectives: Diagnosis of human infection by various species of the bacterial genus Borrelia is mainly reliant on serological testing, polymerase chain reaction (PCR) or culture but such serological tests have been reported to have heterogeneous sensitivities, while Borrelia PCR and culture have been reported as being of modest diagnostic value. It has been suggested that the adjunctive use of the lymphocyte transformation test-memory lymphocyte immunostimulation assay (LTT-MELISA) may be helpful in this regard; however, the clinical usefulness of this assay has been questioned. The Borrelia immunodominant 41-kDa flagellin protein almost always gives rise to a marked human antibody response following infection. It was therefore decided to determine whether the LTT-MELISA detects the human antibody response to this antigen.
Methods: Blood samples from consecutive patients with possible borreliosis attending a clinic were independently tested by both Western blots and LTT-MELISA.
Results: After omitting cases with indeterminate Western blot results and equivocal LTT-MELISA results, multiple linear regression modelling demonstrated that the 41-kDa flagellin immunoglobulin (Ig) M level was predictable from two LTT-MELISA variables (F2,51 = 5.981, P = 0.005). Similarly, the corresponding 41-kDa IgG model also contained two LTT-MELISA variables (F2,57 = 3.700, P = 0.031).
Conclusion: It is concluded that the LTT-MELISA appears to be able to detect the response to this antigen.
背景/目的:人类感染伯氏疏螺旋体的诊断主要依赖于血清学检测、聚合酶链反应(PCR)或培养,但据报道,这种血清学检测具有不同的敏感性,而伯氏疏螺旋体PCR和培养的诊断价值一般。有人建议,辅助使用淋巴细胞转化测试-记忆淋巴细胞免疫刺激试验(LTT-MELISA)可能在这方面有所帮助;然而,这种检测方法的临床有效性一直受到质疑。伯氏疏螺旋体免疫优势41-kDa鞭毛蛋白几乎总是在感染后引起显著的人抗体反应。因此,决定确定LTT-MELISA是否检测到人对该抗原的抗体反应。方法:使用Western blots和LTT-MELISA分别对连续就诊的疑似螺旋体病患者的血液样本进行独立检测。结果:在剔除Western blot结果不确定和LTT-MELISA结果不明确的病例后,多元线性回归模型显示,41-kDa鞭毛蛋白免疫球蛋白(Ig) M水平可通过两个LTT-MELISA变量预测(f2,51 = 5.981, P = 0.005)。同样,对应的41-kDa IgG模型也包含两个LTT-MELISA变量(f2,57 = 3.700, P = 0.031)。结论:LTT-MELISA似乎能够检测到对该抗原的反应。
{"title":"Detection of 41-kDa bacterial flagellin protein by the lymphocyte transformation test-memory lymphocyte immunostimulation assay.","authors":"Basant K Puri, Jean A Monro","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background/objectives: </strong>Diagnosis of human infection by various species of the bacterial genus <i>Borrelia</i> is mainly reliant on serological testing, polymerase chain reaction (PCR) or culture but such serological tests have been reported to have heterogeneous sensitivities, while <i>Borrelia</i> PCR and culture have been reported as being of modest diagnostic value. It has been suggested that the adjunctive use of the lymphocyte transformation test-memory lymphocyte immunostimulation assay (LTT-MELISA) may be helpful in this regard; however, the clinical usefulness of this assay has been questioned. The <i>Borrelia</i> immunodominant 41-kDa flagellin protein almost always gives rise to a marked human antibody response following infection. It was therefore decided to determine whether the LTT-MELISA detects the human antibody response to this antigen.</p><p><strong>Methods: </strong>Blood samples from consecutive patients with possible borreliosis attending a clinic were independently tested by both Western blots and LTT-MELISA.</p><p><strong>Results: </strong>After omitting cases with indeterminate Western blot results and equivocal LTT-MELISA results, multiple linear regression modelling demonstrated that the 41-kDa flagellin immunoglobulin (Ig) M level was predictable from two LTT-MELISA variables (<i>F</i> <sub>2,51</sub> = 5.981, <i>P</i> = 0.005). Similarly, the corresponding 41-kDa IgG model also contained two LTT-MELISA variables (<i>F</i> <sub>2,57</sub> = 3.700, <i>P</i> = 0.031).</p><p><strong>Conclusion: </strong>It is concluded that the LTT-MELISA appears to be able to detect the response to this antigen.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"11 4","pages":"72-77"},"PeriodicalIF":0.0,"publicationDate":"2022-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520187/pdf/ajcei0011-0072.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40391854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A particular group of children developed severe multisystem inflammation associated with current or recent SARS-CoV-2 infection or contact with a COVID-19 patient in the previous few weeks. The condition was defined as multisystem inflammatory syndrome (MIS) in children (MIS-C). As the definition of CDC and WHO is fast widely accepted, the lack of an international consensus on the definition of the syndrome cases, however, leads to some difficulties for clinicians. Additionally, MIS-C shares some immunological, pathological features with the conditions, such as cytokine storm, long COVID and/or post-COVID syndrome. The picture is further complicated by the existence of the syndrome in adults (MIS-A). Therefore, we have compared these conditions from the immunological point of view in our review based on the published case reports, studies, systematic reviews and metaanalyses. This knowledge is essential not only for immunologists. The paediatricians must be familiar with the immunological bases of the syndrome and implement it in on-time recognition and diagnosis and minimize systemic damage of this life-threatening condition at the earliest stage possible. Further investigations still need to be done to find and develop the best effective therapy and prophylactics.
{"title":"Immunological features of the multisystem inflammatory syndrome associated with SARS-CoV-2 in children.","authors":"Snezhina Lazova, Dilyana Gerenska, Yoanna Slabakova, Tsvetelina Velikova","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A particular group of children developed severe multisystem inflammation associated with current or recent SARS-CoV-2 infection or contact with a COVID-19 patient in the previous few weeks. The condition was defined as multisystem inflammatory syndrome (MIS) in children (MIS-C). As the definition of CDC and WHO is fast widely accepted, the lack of an international consensus on the definition of the syndrome cases, however, leads to some difficulties for clinicians. Additionally, MIS-C shares some immunological, pathological features with the conditions, such as cytokine storm, long COVID and/or post-COVID syndrome. The picture is further complicated by the existence of the syndrome in adults (MIS-A). Therefore, we have compared these conditions from the immunological point of view in our review based on the published case reports, studies, systematic reviews and metaanalyses. This knowledge is essential not only for immunologists. The paediatricians must be familiar with the immunological bases of the syndrome and implement it in on-time recognition and diagnosis and minimize systemic damage of this life-threatening condition at the earliest stage possible. Further investigations still need to be done to find and develop the best effective therapy and prophylactics.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"11 4","pages":"64-71"},"PeriodicalIF":0.0,"publicationDate":"2022-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520186/pdf/ajcei0011-0064.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40391855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Caecilie Skejoe, Aida S Hansen, Kristian Stengaard-Pedersen, Peter Junker, Kim Hoerslev-Pedersen, Merete L Hetland, Mikkel Oestergaard, Stinne Greisen, Malene Hvid, Mette Deleuran, Bent Deleuran
Objectives: Rheumatoid arthritis (RA) is a chronic autoimmune disease, that involves both pro- and anti-inflammatory mechanisms. The purpose of the present study is to investigate T-cell immunoglobulin and mucin domain 3 (Tim-3) in RA.
Methods: Plasma levels of soluble (s) Tim-3 in early RA (n=98), were followed, to evaluate association with treatment and disease activity, acquired from a prospective collected biobank (clinicaltrials.gov (NCT00660647)). We also investigate the influence of Tim-3 on spontaneous cytokine production in synovial fluid mononuclear cells (SFMC) from RA patients after addition of neutralizing anti-Tim-3's antibodies, either alone or in combination with neutralizing anti-Programmed Cell death protein 1 (PD-1) antibodies.
Results: Long-time stimulated CD4 T-cells expressed high levels of Tim-3, but tended to decrease their PD-1 expression. Tim-3 expression was exclusively seen co-expressed with PD-1 by CD3, CD4, CD45RO positive cells in the inflamed RA joint. Addition of neutralizing Tim-3 antibodies increased the secretion of IFNγ and MCP-1, in SFMC cultures from RA. Whereas neutralizing anti-PD-1 antibodies showed a broader impact on cytokine production. Finally, we observed that soluble Tim-3 is increased in plasma and is associated with disease activity in early RA.
Conclusion: Taken together, our findings indicate disease-suppressive functions of Tim-3 in RA.
{"title":"T-cell immunoglobulin and mucin domain 3 is upregulated in rheumatoid arthritis, but insufficient in controlling inflammation.","authors":"Caecilie Skejoe, Aida S Hansen, Kristian Stengaard-Pedersen, Peter Junker, Kim Hoerslev-Pedersen, Merete L Hetland, Mikkel Oestergaard, Stinne Greisen, Malene Hvid, Mette Deleuran, Bent Deleuran","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objectives: </strong>Rheumatoid arthritis (RA) is a chronic autoimmune disease, that involves both pro- and anti-inflammatory mechanisms. The purpose of the present study is to investigate T-cell immunoglobulin and mucin domain 3 (Tim-3) in RA.</p><p><strong>Methods: </strong>Plasma levels of soluble (s) Tim-3 in early RA (n=98), were followed, to evaluate association with treatment and disease activity, acquired from a prospective collected biobank (clinicaltrials.gov (NCT00660647)). We also investigate the influence of Tim-3 on spontaneous cytokine production in synovial fluid mononuclear cells (SFMC) from RA patients after addition of neutralizing anti-Tim-3's antibodies, either alone or in combination with neutralizing anti-Programmed Cell death protein 1 (PD-1) antibodies.</p><p><strong>Results: </strong>Long-time stimulated CD4 T-cells expressed high levels of Tim-3, but tended to decrease their PD-1 expression. Tim-3 expression was exclusively seen co-expressed with PD-1 by CD3, CD4, CD45RO positive cells in the inflamed RA joint. Addition of neutralizing Tim-3 antibodies increased the secretion of IFNγ and MCP-1, in SFMC cultures from RA. Whereas neutralizing anti-PD-1 antibodies showed a broader impact on cytokine production. Finally, we observed that soluble Tim-3 is increased in plasma and is associated with disease activity in early RA.</p><p><strong>Conclusion: </strong>Taken together, our findings indicate disease-suppressive functions of Tim-3 in RA.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"11 3","pages":"34-44"},"PeriodicalIF":0.0,"publicationDate":"2022-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301058/pdf/ajcei0011-0034.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40620421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Berta N Restrepo, Katerine Marín, Paola Romero, Margarita Arboleda, Ana L Muñoz, Irene Bosch, Heriberto Vásquez-Serna, Orlando A Torres
The pathogenesis of the severity of chikungunya infection is not yet fully understood.
Objective: To assess the role of the cytokines/chemokines and system of complement in the evolution of chikungunya infection.
Methods: In both acute and chronic phases, we measured the serum levels of 12 cytokines/chemokines and two complement mediators: mannose-binding lectin (MBL) and C3a, in 83 patients with chikungunya infection and ten healthy controls.
Results: During the acute phase, 75.9% of the patients developed musculoskeletal disorders, and in 37.7% of them, these disorders persisted until the chronic phase. In general, patients had higher levels of cytokines than healthy controls, with significant differences for IFN-γ, IL-6, IL-8, IL-10, and MIP-1. Most cytokines exhibited a downward trend during the chronic phase. However, only IL-10, and MIP-1 levels were significantly lower in the chronic phase. Additionally, these levels never decreased to concentrations found in healthy controls. Moreover, MBL levels were significantly higher in the acute phase compared with the chronic phase. C3a levels were significantly higher in patients with musculoskeletal disorder compared with patients without it, in both acute-phase 118.2 (66.5-252.9), and chronic phase 68.5 (64.4-71.3), P < 0.001. Interestingly, C3a levels were significantly higher when patients had a severe disease version. Besides, in the acute phase, C3a levels were higher in patients that suffer arthritis as opposed to when they suffer arthralgia, 194.3 (69.5-282.2), and 70.9 (62.4-198.8), P = 0.013, respectively.
Conclusions: Our results showed an immunological response that persisted until the chronic phase and the role of the complement system in the severity of the disease.
{"title":"Role of cytokines, chemokines, C3a, and mannose-binding lectin in the evolution of the chikungunya infection.","authors":"Berta N Restrepo, Katerine Marín, Paola Romero, Margarita Arboleda, Ana L Muñoz, Irene Bosch, Heriberto Vásquez-Serna, Orlando A Torres","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The pathogenesis of the severity of chikungunya infection is not yet fully understood.</p><p><strong>Objective: </strong>To assess the role of the cytokines/chemokines and system of complement in the evolution of chikungunya infection.</p><p><strong>Methods: </strong>In both acute and chronic phases, we measured the serum levels of 12 cytokines/chemokines and two complement mediators: mannose-binding lectin (MBL) and C3a, in 83 patients with chikungunya infection and ten healthy controls.</p><p><strong>Results: </strong>During the acute phase, 75.9% of the patients developed musculoskeletal disorders, and in 37.7% of them, these disorders persisted until the chronic phase. In general, patients had higher levels of cytokines than healthy controls, with significant differences for IFN-γ, IL-6, IL-8, IL-10, and MIP-1. Most cytokines exhibited a downward trend during the chronic phase. However, only IL-10, and MIP-1 levels were significantly lower in the chronic phase. Additionally, these levels never decreased to concentrations found in healthy controls. Moreover, MBL levels were significantly higher in the acute phase compared with the chronic phase. C3a levels were significantly higher in patients with musculoskeletal disorder compared with patients without it, in both acute-phase 118.2 (66.5-252.9), and chronic phase 68.5 (64.4-71.3), P < 0.001. Interestingly, C3a levels were significantly higher when patients had a severe disease version. Besides, in the acute phase, C3a levels were higher in patients that suffer arthritis as opposed to when they suffer arthralgia, 194.3 (69.5-282.2), and 70.9 (62.4-198.8), P = 0.013, respectively.</p><p><strong>Conclusions: </strong>Our results showed an immunological response that persisted until the chronic phase and the role of the complement system in the severity of the disease.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"11 3","pages":"51-63"},"PeriodicalIF":0.0,"publicationDate":"2022-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301056/pdf/ajcei0011-0051.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40620423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Idiopathic chronic obstructive pulmonary disease (ICOPD) is a prevalent human disease. The etiology of the disease is yet to be clarified. The main aim of this project was to explore serum levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α) and transforming growth factor-beta (TGF-β) in the ICOPD patients in comparison to healthy controls.
Methods: In this cross-sectional study, serum levels of IL-6, TNF-α and TGF-β were evaluated in the 70 non-smoker ICOPD patients and 70 sex and age matched controls, using ELISA technique by the commercial kits from Karmania Pars Gene Company. Analysis of data was performed by parametric independent and Pearson correlation test.
Results: Serum levels of IL-6 and TGF-β, but not TNF-α, were significantly decreased in the ICOPD patients in comparison to controls. Serum levels of IL-6, TNF-α and TGF-β were not altered in the ICOPD male in comparison to female and also in mild when compared to moderate ICOPD patients.
Conclusions: Down-regulation of TGF-β may be the main risk factor for deterioration of inflammation in the ICOPD patients. Decreased IL-6 may be related to the idiopathic type of COPD.
{"title":"Down-regulation of transforming growth factor-beta and interleukin-6 serum levels in the idiopathic chronic obstructive pulmonary disease.","authors":"Reza Bahramabadi, Hassan Yousefi-Daredor, Sahar Rezaeinejad, Mohammadtaghi Rezayati, Mohammad Kazemi Arababadi","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Idiopathic chronic obstructive pulmonary disease (ICOPD) is a prevalent human disease. The etiology of the disease is yet to be clarified. The main aim of this project was to explore serum levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α) and transforming growth factor-beta (TGF-β) in the ICOPD patients in comparison to healthy controls.</p><p><strong>Methods: </strong>In this cross-sectional study, serum levels of IL-6, TNF-α and TGF-β were evaluated in the 70 non-smoker ICOPD patients and 70 sex and age matched controls, using ELISA technique by the commercial kits from Karmania Pars Gene Company. Analysis of data was performed by parametric independent and Pearson correlation test.</p><p><strong>Results: </strong>Serum levels of IL-6 and TGF-β, but not TNF-α, were significantly decreased in the ICOPD patients in comparison to controls. Serum levels of IL-6, TNF-α and TGF-β were not altered in the ICOPD male in comparison to female and also in mild when compared to moderate ICOPD patients.</p><p><strong>Conclusions: </strong>Down-regulation of TGF-β may be the main risk factor for deterioration of inflammation in the ICOPD patients. Decreased IL-6 may be related to the idiopathic type of COPD.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"11 3","pages":"45-50"},"PeriodicalIF":0.0,"publicationDate":"2022-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9301057/pdf/ajcei0011-0045.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40620422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zeineb A El-Sayed, Rasha H El-Owaidy, Waleed N Harb, Ghada A Shousha
Background: There are insufficient data concerning COVID-19 severity among asthmatic children.
Aim: to evaluate the impact of asthma on COVID-19 severity and outcome.
Patients and methods: We carried out an observational study that comprised 2 matched groups of children with confirmed/probable COVID-19: 30 with and 32 without asthma aged 6-18 years, who were enrolled consecutively from Children's Hospital, Ain Shams University, Egypt. COVID-19 clinical presentations, laboratory and radiological abnormalities, severity and outcome were compared between the 2 groups. Asthma severity and control were assessed based on GINA 2020.
Results: The asthmatic COVID-19 children were 9 boys and 21 girls, with median age 9 years, IQR: 8-12 years. The non-asthmatic COVID-19 group included 18 males and 14 females with median age 9.5 years, IQR: 7-12.5 years. Clinical manifestations of COVID-19 were comparable among the 2 groups, except for wheezes which were more frequently encountered as a COVID-19 manifestation among the asthmatics (p=0.001). Multisystem inflammatory syndrome (MIS-c) was diagnosed in one asthmatic and 3 non-asthmatic patients. The asthmatic group had higher frequency of serum ferritin, LDH and D-dimer elevations compared to the non-asthmatic peers (p values 0.014, 0.001, and 0.015 respectively). Based on CO-RAD classification, 70% of the asthmatic patients had CO-RAD score of 5 versus 6.3 % among the non-asthmatic group with significant differences between the 2 groups in their CO-RAD scores (P=0.002). COVID-19 severity was comparable among the studied groups (P=0.775), as well as COVID-19 outcome and duration of hospital stay (p values 0.999, and 0.655, respectively).
Conclusion: From our limited sample sized study, childhood asthma did not pose a significant impact on COVID-19 severity and outcome. Further longitudinal studies are warranted to validate our conclusion and investigate the relation of COVID-19 severity and outcome to allergen immunotherapy and the use of biologicals for asthma treatment.
{"title":"COVID-19 in a group of children with asthma: presentation, severity, and outcome.","authors":"Zeineb A El-Sayed, Rasha H El-Owaidy, Waleed N Harb, Ghada A Shousha","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>There are insufficient data concerning COVID-19 severity among asthmatic children.</p><p><strong>Aim: </strong>to evaluate the impact of asthma on COVID-19 severity and outcome.</p><p><strong>Patients and methods: </strong>We carried out an observational study that comprised 2 matched groups of children with confirmed/probable COVID-19: 30 with and 32 without asthma aged 6-18 years, who were enrolled consecutively from Children's Hospital, Ain Shams University, Egypt. COVID-19 clinical presentations, laboratory and radiological abnormalities, severity and outcome were compared between the 2 groups. Asthma severity and control were assessed based on GINA 2020.</p><p><strong>Results: </strong>The asthmatic COVID-19 children were 9 boys and 21 girls, with median age 9 years, IQR: 8-12 years. The non-asthmatic COVID-19 group included 18 males and 14 females with median age 9.5 years, IQR: 7-12.5 years. Clinical manifestations of COVID-19 were comparable among the 2 groups, except for wheezes which were more frequently encountered as a COVID-19 manifestation among the asthmatics (p=0.001). Multisystem inflammatory syndrome (MIS-c) was diagnosed in one asthmatic and 3 non-asthmatic patients. The asthmatic group had higher frequency of serum ferritin, LDH and D-dimer elevations compared to the non-asthmatic peers (<i>p</i> values 0.014, 0.001, and 0.015 respectively). Based on CO-RAD classification, 70% of the asthmatic patients had CO-RAD score of 5 versus 6.3 % among the non-asthmatic group with significant differences between the 2 groups in their CO-RAD scores (P=0.002). COVID-19 severity was comparable among the studied groups (P=0.775), as well as COVID-19 outcome and duration of hospital stay (<i>p</i> values 0.999, and 0.655, respectively).</p><p><strong>Conclusion: </strong>From our limited sample sized study, childhood asthma did not pose a significant impact on COVID-19 severity and outcome. Further longitudinal studies are warranted to validate our conclusion and investigate the relation of COVID-19 severity and outcome to allergen immunotherapy and the use of biologicals for asthma treatment.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"11 6","pages":"92-102"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845840/pdf/ajcei0011-0092.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10607202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: definite figures of allergy to wheat and strawberries in Egypt are lacking. We investigated IgE-mediated sensitization to wheat and strawberry among a group of allergic children, and the relation between wheat and strawberry sensitization.
Patients and methods: This study comprised 256 children, with physician-diagnosed allergy: bronchial asthma (98 patients), allergic rhinitis (28 patients), atopic dermatitis (53 patients) and food allergy (10 patients). Sensitization to wheat and strawberry was assessed using prick testing, followed by oral challenge test to prove allergy.
Results: Wheat sensitization was observed in 9.4% of the studied children with confirmed allergy in 0.4%. Strawberry sensitization was observed in 7.8% of patients, with 2% confirmed allergy. Either sensitization did not influence response of allergy to treatment. Wheat and strawberry sensitizations were positively correlated.
Conclusion: Wheat and strawberry allergies are not common among Egyptian children with allergic disorders; and did not impact the response to allergy treatment.
{"title":"Sensitizations to wheat and strawberry: are they a tangible threat to atopic Egyptian.","authors":"Zeinab Awad El-Sayed, Heba Sakr, Ghada Abdel Haleem Shousha","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>definite figures of allergy to wheat and strawberries in Egypt are lacking. We investigated IgE-mediated sensitization to wheat and strawberry among a group of allergic children, and the relation between wheat and strawberry sensitization.</p><p><strong>Patients and methods: </strong>This study comprised 256 children, with physician-diagnosed allergy: bronchial asthma (98 patients), allergic rhinitis (28 patients), atopic dermatitis (53 patients) and food allergy (10 patients). Sensitization to wheat and strawberry was assessed using prick testing, followed by oral challenge test to prove allergy.</p><p><strong>Results: </strong>Wheat sensitization was observed in 9.4% of the studied children with confirmed allergy in 0.4%. Strawberry sensitization was observed in 7.8% of patients, with 2% confirmed allergy. Either sensitization did not influence response of allergy to treatment. Wheat and strawberry sensitizations were positively correlated.</p><p><strong>Conclusion: </strong>Wheat and strawberry allergies are not common among Egyptian children with allergic disorders; and did not impact the response to allergy treatment.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":"11 6","pages":"84-91"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845839/pdf/ajcei0011-0084.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10607205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}